Skip to main content

Advertisement

Table 1 Key results of the clinical trials included in the present analysis

From: Treatment of hepatitis C virus genotype 4 in the DAA era

Clinical trial or field experience n° of patients with G4-infection Treatment SVR rate in GT4 patients
Ruane 2015 [8] 34 SOF + RBV 68–93%
Feld 2015 [9] 116 SOF/VEL 100%
Curry 2015 [10] 8 SOF/VEL 100%
Gane 2016 [11] 17 SOF/VEL + VOX 58%
Bourliere 2017 [12] 41 (POLARIS-1 + POLARIS-4) SOF/VEL + VOX 97%
Colombo 2017 [13] 10 SOF/LDV 100%
Kholi 2015 [14] 21 SOF/LDV 95%
Buti 2017 [15] 40 SMV/SOF 100%
El Raziky 2017 [16] 63 SMV/SOF 92%
Kwo 2017 [17] 37 EBR + GZR 89%
Waked [18] 160 OBV/PTV/R/RBV 93–94%
Hézode 2015 [19] 135 OBV/PTV/r ± RBV 100% with RBV, 91% without RBV
Forns [20] 16 GLI/PIB 100%
Kwo [42] 22(SURVEYOR-I and SURVEYOR-II) GLI/ PIB 100%
Asselah [21] SURVEYOR-II Part 4, ENDURANCE-4 and ENDURANCE-2) GLI/ PIB 93% 8 week treatment 99% 12 week treatment
Yakoot [22] 120 (randomized 60 in 12 weeks regimen and 60 in response tailored regimen) SOF + DAC 96.7% in the fixed regimen 98.4% in the response tailored regimen
El-Khayat [23] 551 cirrotic patients (432 naïve, 119 treatment experienced) SOF + DAC + RBV 92%in naïve 87% in experienced
Willemse [24] 53 (naïve and IFN experienced) SOF + SIM 92%
Degre [25] 87, IFN experienced SOF + SIM ± RBV 87.4%
Elsharkawy 2017 [26] 8742 (F3) 5667 (F3) SOF/peg/IFN-RBV SOF/RBV 94% 79%
Asselah 2017 [27] 67 naïve, F0-F2 SIM + PEG IFN 97%
Ioannou [28] 135 (two arm: 104, 31) SOF/LDV ± RBV and OBV/PTV/r ± RBV 89.6%
Crespo [29] 152 (two arm:130 and 122) SOF/LDV ± RBV and OBV/PTV/r ± RBV 95.4 and 96.2%
Welzel [30] 53 OBV/PTV/r ± RBV 100%
Perello [31] 87 (73% cirrhosis, 35% treatment naïve) OBV/PTV/r ± RBV 100%
Petta 2017 [32] 17 OBV/PTV/r ± RBV 94%
Wedemeyer 2017 [33] 112, 19 cirrhosis OBV/PTV/r ± RBV 96,5%
Komatsu [34] 26 EBR + GZR 100%
Maria 2017 [35] 7 SOF ± SIM or DAC or LDV ± RBV 100%
Hezode 2016 [36] 215 SOF + DAC 91%
Babatin 2017 [37] 40 35% cirrhotic; treatment-experienced 52.5% SOF + DAC + RBV 100%
Abad 2017 [38] 35 OBV/PTV/r 100%
Ponziani 2017 [46] 8 OBV/PTV/r 100%
Manns 2016 [43] 37 SOF/LDV + RBV 81%
  1. GT4 HCV Genotype 4, SOF sofosbuvir, VEL velpatasvir, VOX voxilaprevir, LDV ledipasvir, SIM simeprevir, RBV ribavirin, EBR elbasvir, GZR grazoprevir, OBV ombitasvir, PTV paritaprevir, GLI glicaprevir, PIB pibrentasvir, DAC daclatasvir